Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
about
My treatment approach to rheumatoid arthritisPredictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Adalimumab for the treatment of rheumatoid arthritisEffects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyEvaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.TNFR2 Deficiency Acts in Concert with Gut Microbiota To Precipitate Spontaneous Sex-Biased Central Nervous System Demyelinating Autoimmune Disease.The challenging interplay between rheumatoid arthritis, ageing and comorbidities.Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryTwenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis populationSex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry.Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients.Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumabComorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activityAssociation between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.Does disease activity at the start of biologic therapy influence health care costs in patients with RA?Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health SystemA predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.An immunological biomarker to predict MTX response in early RA.Sex, Symptom Severity, and Quality of Life in Rheumatology.Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisUnmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus
P2860
Q26829955-C4656F57-99F7-418A-ABB2-2B373BD06C0FQ27692641-530B26A6-9352-45A3-8D44-CCBE8D858F6EQ28282655-602C35C6-314C-4F63-8A3B-708093E23EE4Q30984829-86A21D9A-6878-4A5A-9CCC-6F437300EAD8Q33984823-3BCDC6C9-A427-47A3-9600-B704AC87FB14Q34818608-1DE68299-D7B2-4183-B53B-3D0388BD9B12Q35047250-BC350A84-79A1-4A40-97A8-C8D48CE5A87EQ35811308-14211A19-2CB4-4B6E-A99A-CED0F93629F9Q36000249-7A86F386-E911-442A-A434-D45B3720CBF5Q36024297-75E8F1C5-3472-43AB-86C0-8D9181C0A40CQ36279419-E6E3EB9E-EEED-4181-A3A7-6B1A2A2ACBB1Q36584051-D87363FB-84CE-4EEB-81FF-3B20B86B3D0CQ36670140-D8C54C79-6AF7-4126-9FA3-E8A810EAECFBQ36706945-B3C3C050-6C5C-4770-895C-762D0D1E9706Q37118948-8C60DB17-71BA-458C-9B2E-096D32E1A1CBQ37177578-20F959A5-862E-4AFF-9DE4-F5824D02E8C9Q37195347-ECBFD701-91BF-4F0C-ABB4-5C4B265BD686Q37347655-C441B42C-E8B7-4A58-A929-92CD05D33305Q37471597-0BDFC761-BB6A-46A8-B2AA-60C212B9DA00Q37873493-D17E86DA-4B2F-41D8-80EA-93B16EB5290AQ38185644-D9BDED7B-D29A-4E96-9CFF-0F88033A926CQ38238931-53EAA65F-0B48-4E56-A9A3-0F58F31B81E9Q39328173-EF4FD1EA-CDF6-46BC-AD1D-AABD7D240485Q40314992-6E949168-3859-430E-99F0-4F392F6EB8F5Q40875239-9C6E85CF-23B5-40F4-8969-C729F5D34F4CQ41183360-4DCCBF49-728B-4398-8564-FAABEACF0AA2Q42734907-5C905387-9F72-4DA5-A9E6-1927EBF49F1DQ43686385-7B888E88-143C-4C15-807C-E6E8DA8DC908Q45830734-578EA142-7604-4119-A448-D1CCA03E3F09Q47671088-29916C94-BA8F-42DA-AE33-9FBB2A8CC671Q51104726-24B94C9F-BD1C-4AAE-B967-D9F8A4082B97Q56975651-F5583917-F595-4051-9F4D-70014D6C8CD0Q57115262-7A0415C0-FA99-4BCF-B5CD-3B9EF973D51C
P2860
Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Clinical remission and/or mini ...... open-label, twelve-week study.
@en
Clinical remission and/or mini ...... open-label, twelve-week study.
@nl
type
label
Clinical remission and/or mini ...... open-label, twelve-week study.
@en
Clinical remission and/or mini ...... open-label, twelve-week study.
@nl
prefLabel
Clinical remission and/or mini ...... open-label, twelve-week study.
@en
Clinical remission and/or mini ...... open-label, twelve-week study.
@nl
P2093
P356
P1476
Clinical remission and/or mini ...... open-label, twelve-week study.
@en
P2093
Hartmut Kupper
Indalecio Monteagudo-Sáez
Kristina Unnebrink
René-Marc Flipo
Sonja Kary
P356
10.1002/ART.23247
P577
2008-01-01T00:00:00Z